|
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer. |
|
|
Employment - Analysis Group |
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Kiniksa (Inst); LivaNova (Inst); Mallinckrodt (Inst); Medtronic (Inst); Merck (Inst); Novartis (Inst); Novo Nordisk (Inst); Novo Nordisk (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Seagen (Inst); Takeda (Inst); Vertex (Inst); ViiV Healthcare (Inst) |
Expert Testimony - Medtronic (Inst) |
|
|
Research Funding - Ayala Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Pfizer (Inst) |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Other Relationship - Analysis Group |
|
|
Research Funding - Pfizer (Inst); Sanofi (Inst); United Therapeutics (Inst); Vertex (Inst) |
|
|
Research Funding - Astellas Pharma (Inst); Biomarin (Inst); Genentech/Roche (Inst); Janssen (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Genomic Health (I) |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Exact Sciences; Ferring; Janssen Biotech; Merck; Myovant Sciences; Pfizer; Sanofi |
Speakers' Bureau - AstraZeneca; Sanofi |
Research Funding - Bayer (Inst); Diasorin; GenomeDx (Inst); Janssen Biotech (Inst); MDxHealth (Inst); Merck; Myriad Genetics (Inst); OPKO Diagnostics (Inst); Progenika (Inst) |
Travel, Accommodations, Expenses - Sanofi |